The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials

JAMA. 2021 Jan 19;325(3):219-220. doi: 10.1001/jama.2020.25053.

Authors

Annette Rid¹, Marc Lipsitch², Franklin G Miller³

Affiliations

¹ Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, Maryland.
² Center for Communicable Disease Dynamics, Department of Epidemiology, Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
³ Weill Cornell Medical College, New York, New York.

PMID: 33315080
DOI: 10.1001/jama.2020.25053

No abstract available

Publication types

Research Support, N.I.H., Intramural

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage*
COVID-19 Vaccines / supply & distribution
Clinical Trials as Topic / ethics*
Health Equity / ethics
Humans
Patient Selection / ethics
Placebos / administration & dosage*
SARS-CoV-2 / immunology*
Vaccination / ethics*

Substances

COVID-19 Vaccines
Placebos